Trilogy Capital Inc. Buys New Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Trilogy Capital Inc. purchased a new stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 83,500 shares of the company's stock, valued at approximately $422,000. Trilogy Capital Inc. owned 0.07% of Humacyte as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Brookstone Capital Management acquired a new position in Humacyte in the fourth quarter worth $56,000. ACT Wealth Management LLC bought a new stake in shares of Humacyte during the fourth quarter valued at about $57,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte during the third quarter valued at about $75,000. FORA Capital LLC bought a new stake in shares of Humacyte during the third quarter valued at about $96,000. Finally, Insigneo Advisory Services LLC bought a new stake in shares of Humacyte during the third quarter valued at about $109,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Insider Activity

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the transaction, the chief executive officer now owns 2,419,712 shares of the company's stock, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 over the last 90 days. 11.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Benchmark lifted their target price on Humacyte from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, December 23rd. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, January 21st. TD Cowen reissued a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Finally, BTIG Research reissued a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Humacyte presently has a consensus rating of "Buy" and a consensus price target of $13.71.

Humacyte Price Performance

Shares of HUMA traded down $0.06 on Monday, reaching $4.10. 1,293,930 shares of the stock traded hands, compared to its average volume of 2,302,054. The firm has a market cap of $515.40 million, a price-to-earnings ratio of -3.05 and a beta of 1.30. Humacyte, Inc. has a 12 month low of $2.81 and a 12 month high of $9.97. The stock's 50-day moving average price is $4.52 and its 200-day moving average price is $5.38.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.08). During the same period in the prior year, the business earned ($0.25) earnings per share. As a group, equities research analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.